Thermo Fisher Scientific Inc. (TMO) insider exercises 104,000 options and sells shares

Rhea-AI Filing Summary

Thermo Fisher Scientific Inc. executive Michel Lagarde reported multiple stock option exercises and related stock sales. As Executive Vice President & COO, he filed a Form 4 for transactions dated December 2 and 3, 2025.

On December 2, Lagarde exercised options to acquire 36,000 shares of common stock at an exercise price of $105.17 per share, then sold 30,000 shares at a weighted average price of $581.92. On December 3, he exercised options for another 68,000 shares at $105.17, and sold 29,479 shares at a weighted average price of $583.33 plus 2,521 shares at a weighted average price of $584.11.

After these transactions, Lagarde directly held 65,479.909 shares of Thermo Fisher common stock and 18,637 stock options with a $105.17 exercise price expiring on July 20, 2026, which had vested in two equal installments on August 29, 2017 and 2020.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lagarde Michel

(Last) (First) (Middle)

168 THIRD AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President & COO

3. Date of Earliest Transaction (Month/Day/Year)
12/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/02/2025		M		36,000	A	$105.17	59,479.909	D
Common Stock	12/02/2025		S		30,000	D	$581.92(1)	29,479.909	D
Common Stock	12/03/2025		M		68,000	A	$105.17	97,479.909	D
Common Stock	12/03/2025		S		29,479	D	$583.33(2)	68,000.909	D
Common Stock	12/03/2025		S		2,521	D	$584.11(3)	65,479.909	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$105.17	12/02/2025		M			36,000	(4)	07/20/2026	Common Stock	36,000	$0	86,637	D
Stock Option (Right to Buy)	$105.17	12/03/2025		M			68,000	(4)	07/20/2026	Common Stock	68,000	$0	18,637	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.90 to $582.33, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.03 to $583.96, inclusive.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.00 to $584.533, inclusive.

4. The option vested in two equal installments on August 29, 2017 and 2020.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Melodie T. Morin, Attorney-in-Fact for Michel Lagarde	12/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity at Thermo Fisher Scientific (TMO) is disclosed in this Form 4?

The Form 4 discloses that Executive Vice President & COO Michel Lagarde exercised stock options and sold shares of Thermo Fisher Scientific Inc. common stock on December 2 and 3, 2025.

How many Thermo Fisher (TMO) shares did Michel Lagarde acquire and sell?

Lagarde exercised options to acquire 36,000 shares on December 2 and 68,000 shares on December 3 at an exercise price of $105.17. He sold 30,000 shares on December 2, then 29,479 shares and 2,521 shares in separate transactions on December 3.

What prices were Thermo Fisher (TMO) shares sold for in these insider transactions?

The reported sales used weighted average prices: $581.92 on December 2, and on December 3, $583.33 for 29,479 shares and $584.11 for 2,521 shares. Each price reflects multiple trades within the stated ranges.

How many Thermo Fisher (TMO) shares and options does Michel Lagarde hold after the transactions?

After the reported transactions, Lagarde directly owned 65,479.909 shares of Thermo Fisher common stock and held 18,637 stock options with a $105.17 exercise price expiring on July 20, 2026.

What are the key terms of Michel Lagardes Thermo Fisher (TMO) stock options?

The disclosed stock options have a $105.17 exercise price and expire on July 20, 2026. According to the footnotes, the option vested in two equal installments on August 29, 2017 and August 29, 2020.

How are the reported Thermo Fisher (TMO) sale prices calculated in this Form 4?

The filing states that each reported sale price is a weighted average price, with shares sold in multiple transactions within price ranges from $581.90 to $584.533. Full price breakdowns are available upon request from Thermo Fisher Scientific Inc. or the reporting person.